Table 3.
Parameters | Baseline | Follow-Up | ||||
---|---|---|---|---|---|---|
All | Males | Females | All | Males | Females | |
N (M/F) | 100 | 54 | 46 | 100 | 54 | 46 |
Age | −0.21 * | −0.11 | −0.34 * | −0.04 | −0.03 | 0.15 |
BMI | −0.24 * | −0.26 | −0.18 | −0.29 ** | −0.16 | −0.24 |
WHR | −0.26 * | −0.43 ** | −0.36 * | 0.08 | −0.06 | −0.31 |
Systolic BP | 0.02 | 0.03 | −0.10 | −0.03 | −0.02 | −0.30 |
Diastolic BP | −0.06 | −0.12 | −0.04 | 0.13 | 0.18 | −0.05 |
Glucose | −0.20 | −0.38 ** | −0.15 | −0.12 | −0.05 | −0.36 * |
Total-Cholesterol | 0.02 | 0.01 | 0.10 | 0.10 | 0.10 | 0.10 |
HDL-Cholesterol | −0.25 * | −0.41 ** | −0.06 | 0.12 | 0.15 | 0.25 |
Triglycerides # | −0.22 * | −0.24 | −0.25 | −0.13 | −0.05 | −0.22 |
Vitamin D | 0.26 * | 0.08 | 0.43 ** | −0.23 * | −0.18 | −0.32 * |
Apo-CI # | −0.26 * | −0.15 | −0.24 | −0.37 ** | −0.01 | −0.51 ** |
Apo-H | −0.10 | −0.02 | −0.01 | −0.26 * | −0.36 * | −0.17 |
Apo-Al # | 0.44 ** | 0.41 ** | 0.49 ** | 0.13 | −0.10 | 0.45 ** |
Apo-CIII # | 0.45 ** | 0.42 ** | 0.51 ** | 0.45 ** | 0.26 | 0.48 ** |
Apo-E # | 0.54 ** | 0.60 ** | 0.51 ** | 0.49 ** | 0.35 * | 0.56 ** |
Apo-AII # | 0.42 ** | 0.43 ** | 0.32 * | 0.44 ** | 0.11 | 0.58 ** |
Apo-B # | 0.27 * | 0.31 * | 0.18 | 0.34 ** | 0.10 | 0.47 ** |
Apo-CII # | 0.39 ** | 0.38 ** | 0.36 * | 0.41 ** | 0.22 | 0.37 * |
Note: Data presented as correlation coefficient (r); # denotes non-normal variables which were log-transformed before analysis; * denotes significance at 0.05 level; ** denotes significance at 0.01 level.